Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥1,755 JPY
Change Today -1.00 / -0.06%
Volume 1.3M
As of 2:00 AM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).

kyowa hakko kirin co ltd (4151) Snapshot

Open
¥1,754
Previous Close
¥1,756
Day High
¥1,765
Day Low
¥1,725
52 Week High
04/28/15 - ¥1,804
52 Week Low
01/7/15 - ¥1,094
Market Cap
1.0T
Average Volume 10 Days
1.2M
EPS TTM
¥25.90
Shares Outstanding
576.5M
EX-Date
06/26/15
P/E TM
67.8x
Dividend
¥25.00
Dividend Yield
1.42%
Current Stock Chart for KYOWA HAKKO KIRIN CO LTD (4151)

Related News

No related news articles were found.

kyowa hakko kirin co ltd (4151) Related Businessweek News

No Related Businessweek News Found

kyowa hakko kirin co ltd (4151) Details

Kyowa Hakko Kirin Co., Ltd. manufactures and markets pharmaceuticals and bio-chemicals primarily in Asia, Europe, and the United States. The company’s Pharmaceuticals segment researches, develops, produces, and sells ethical drugs for the treatment of various diseases, including renal anemia, oncology, allergies, and hypertension. Its principal ethical drugs include NESP/ESPO, an ESA formulation; REGPARA, a secondary hyperparathyroidism; CONIEL, a hypertension and angina pectoris; ONGLYZA, a treatment for type 2 diabetes; GRAN, a G-CSF agent; Fentos, a transdermal product; POTELIGEO, an adult T-cell leukemia-lymphoma; Romiplate, a chronic idiopathic thrombocytopenic purpur; ALLELOCK, an antiallergic agent; Patanol antiallergic eye drops; ASACOL, an ulcerative colitis treatment; NOURIAST, an antiparkinsonian agent; and DEPAKENE, an antiepileptic agent. This segment also offers in vitro diagnostic reagents, such as POTELIGEO tests and Determiner clinical chemistry diagnostic reagents. The company’s Bio-chemicals segment produces and sells amino acids, nucleotides, and related compounds for use in pharmaceuticals and their intermediates, health foods, dietary supplements, and cosmetics. This segment also produces plant growth regulators; designs and installs plant facilities and equipment; manufactures active pharmaceutical ingredients, pharmaceutical intermediates, industrial raw materials, and health care products; sale of fine chemicals; and is involved in mail-order sale of healthcare products in Japan. In addition, the company is engaged in pharmaceuticals licensing, as well as insurance, wholesale, and retail activities. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Hakko Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

7,424 Employees
Last Reported Date: 03/13/15
Founded in 1949

kyowa hakko kirin co ltd (4151) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kyowa hakko kirin co ltd (4151) Key Developments

Kyowa Hakko Kirin Co., Ltd. Announces Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Earnings Guidance for the Six Months Ended June 30, 2015 and Full Year Ending December 31, 2015; Reports Impairment Charges for the First Quarter Ended March 31, 2015

Kyowa Hakko Kirin Co., Ltd. announced consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company reported net sales of JPY 89.5 billion against JPY 86 billion a year ago. Operating income (prior to amortization of goodwill) was JPY 11.6 billion against JPY 14.7 billion a year ago. Operating income was JPY 9.3 billion against JPY 12.4 billion a year ago. Ordinary income was JPY 8 billion against JPY 12 billion a year ago. Income before income taxes and minority interests was JPY 8.2 billion against JPY 12.3 billion a year ago. Net income was JPY 4.6 billion against JPY 6.3 billion a year ago. EPS prior to amortization of goodwill was JPY 12.65 against JPY 15.80 a year ago. Capital expenditure (property, plant and equipment) was JPY 5.6 billion against JPY 5.3 billion a year ago. Fully diluted net income per share was JPY 8.41 against JPY 11.56 a year ago. Net sales increased due mainly to the growth in sales of new products as well as the impact of Archimedes Pharma Limited, which was acquired in 2014. Meanwhile, operating income declined due mainly to the increase in research and development expenses for late-stage development products. Ordinary income and net income declined due mainly to the drop in operating income and an increase in share of loss of entities accounted for using equity method. For the full year ending December 31, 2015 on consolidated basis, the company expects net sales of JPY 354.0 billion, operating income (prior to amortization of goodwill) of JPY 50.7 billion, operating income of JPY 41.5 billion, ordinary income of JPY 34 billion, net income of JPY 18.5 billion and income before income taxes and minority interests of JPY 31.5 billion. EPS prior to amortization of goodwill is to be JPY 50.71. Capital expenditure (property, plant and equipment) is to be JPY 24.2 billion. Depreciation and amortization expenses are to be JPY 22.6 billion. Amortization of intangible assets is to be JPY 10.2 billion. Net income per share is to be JPY 33.80. Full half year ending June 30, 2015 on consolidated basis, the company expects net sales of JPY 172 billion, operating income (prior to amortization of goodwill) of JPY 21.1 billion, operating income of JPY 16.5 billion. Capital expenditure (property, plant and equipment) is to be JPY 12.8 billion. Depreciation and amortization expenses are to be JPY 11.1 billion. Amortization of intangible assets is to be JPY 5.2 billion. The company reported impairment loss of JPY 205 million for the first quarter ended March 31, 2015.

Kyowa Hakko Kirin Co., Ltd., Q1 2015 Earnings Call, Apr 28, 2015

Kyowa Hakko Kirin Co., Ltd., Q1 2015 Earnings Call, Apr 28, 2015

Kyowa Hakko Kirin Co., Ltd. Completes New Research Building in Fuji Research Park

Kyowa Hakko Kirin Co., Ltd. completed the construction of the new research building, IK8, in Fuji Research Park in Suntou-gun, Shizuoka, Japan. The construction of the IK8 building is part of Kyowa Hakko Kirin's strategy to transfer the Chemical Process R&D Laboratories (Sakai city, Osaka) to Fuji Research Park. The IK8 building will integrate the function of the drug discovery chemical research at Fuji Research Park and the industrialization research at the Chemical Process R&D Laboratories. The IK8 building will be equipped with laboratories for general synthetic chemistry, scale-up studies and optimization of manufacturing processes needed for manufacturing, R&D into synthetic pharmaceuticals. It is to construct research facilities that are safe and environmentally friendly.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4151:JP ¥1,755.00 JPY -1.00

4151 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Genmab A/S kr542.50 DKK +11.50
ImmunoGen Inc $8.42 USD +0.03
Insys Therapeutics Inc $54.75 USD +1.36
MorphoSys AG €65.14 EUR -2.36
Seattle Genetics Inc $34.20 USD +0.17
View Industry Companies
 

Industry Analysis

4151

Industry Average

Valuation 4151 Industry Range
Price/Earnings 67.8x
Price/Sales 2.8x
Price/Book 1.6x
Price/Cash Flow 27.4x
TEV/Sales 2.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KYOWA HAKKO KIRIN CO LTD, please visit www.kyowa-kirin.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.